Characterisation of new efaroxan derivatives for use in purification of imidazoline-binding sites

The insulin secretagogue activity of certain imidazoline compounds is mediated by a binding site associated with ATP-sensitive K + (K ATP) channels in the pancreatic β-cell. We describe the effects of a series of structural modifications to efaroxan on its activity at this site. Substitution of amin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 1998-08, Vol.355 (1), p.67-76
Hauptverfasser: Chan, Susan L.F., Pallett, Anna L., Clews, John, Ramsden, Christopher A., Chapman, J.C., Kane, Charlotte, Dunne, Mark J., Morgan, Noel G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The insulin secretagogue activity of certain imidazoline compounds is mediated by a binding site associated with ATP-sensitive K + (K ATP) channels in the pancreatic β-cell. We describe the effects of a series of structural modifications to efaroxan on its activity at this site. Substitution of amino-, nitro- or azide- groups onto the 5-position of the benzene ring of efaroxan did not significantly affect the functional interaction of the ligand with the islet imidazoline binding site. Modification of the imidazoline ring to an imidazole to generate 2-(2-ethyl-2,3-dihydrobenzo[ b]furan-2-yl)-1 H-imidazole (KU14R) resulted in loss of secretagogue activity. Indeed, this reagent appeared to act as an imidazoline antagonist since it blocked the secretory responses to imidazoline compounds and also inhibited the blockade of β-cell K ATP channels by efaroxan in patch clamp experiments. Application of KU14R alone resulted in a modest reduction in K ATP channel opening, suggesting that it may display weak partial agonism, at least in patch-clamp experiments.
ISSN:0014-2999
1879-0712
DOI:10.1016/S0014-2999(98)00466-X